StockMacro
Menu

Kodiak Sciences

$97.17 +170% in 6 monthsMarket cap $6.4B

KOD on XNAS, Health Care, Kodiak Sciences Inc, job postings

Measures activity, not value. Not investment advice.

Shares up 396% in a year as insiders bought $181.3M in 90 days, while 12-month losses reached $246.8M.

  • BadShort interest at 12% of shares, with 9.3 days to cover
  • BadFree cash flow -$172.8M against cash of $88.7M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
124
Website
kodiak.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 30 Mar 2027 (an estimate: a year ago it reported on 31 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $66.2M.
Quarter to 31 Dec 2021: revenue –, net income -$93.2MQuarter to 31 Mar 2022: revenue –, net income -$95.7MQuarter to 30 Jun 2022: revenue –, net income -$90.6MQuarter to 30 Sep 2022: revenue –, net income -$77.0MQuarter to 31 Dec 2022: revenue –, net income -$70.4MQuarter to 31 Mar 2023: revenue –, net income -$70.8MQuarter to 30 Jun 2023: revenue –, net income -$80.2MQuarter to 30 Sep 2023: revenue –, net income -$50.0MQuarter to 31 Dec 2023: revenue –, net income -$59.5MQuarter to 31 Mar 2024: revenue –, net income -$43.0MQuarter to 30 Jun 2024: revenue –, net income -$45.1MQuarter to 30 Sep 2024: revenue –, net income -$43.9MQuarter to 31 Dec 2024: revenue –, net income -$44.1MQuarter to 31 Mar 2025: revenue –, net income -$57.5MQuarter to 30 Jun 2025: revenue –, net income -$54.3MQuarter to 30 Sep 2025: revenue –, net income -$61.5MQuarter to 31 Dec 2025: revenue –, net income -$56.7MQuarter to 31 Mar 2026: revenue –, net income -$58.2MQuarter to 30 Jun 2026: revenue –, net income -$65.6MQuarter to 30 Sep 2026: revenue –, net income -$66.2M
31 Dec 2021RevenueNet incomeNet losstallest bar $95.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$66.2M
30 Jun 2026–-$65.6M
31 Mar 2026–-$58.2M
31 Dec 2025–-$56.7M
30 Sep 2025–-$61.5M
30 Jun 2025–-$54.3M
31 Mar 2025–-$57.5M
31 Dec 2024–-$44.1M
30 Sep 2024–-$43.9M
30 Jun 2024–-$45.1M
31 Mar 2024–-$43.0M
31 Dec 2023–-$59.5M
30 Sep 2023–-$50.0M
30 Jun 2023–-$80.2M
31 Mar 2023–-$70.8M
31 Dec 2022–-$70.4M
30 Sep 2022–-$77.0M
30 Jun 2022–-$90.6M
31 Mar 2022–-$95.7M
31 Dec 2021–-$93.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$246.8M -$217.3M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$4.08 -$4.12
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$172.8M -$127.3M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $88.7M $72.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – -$72.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.19
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 505 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Kodiak SciencesKOD (this company) $6.4Bloss–––
ImmunityBioIBRX $6.4Bloss35.1+121%-608%
ImmunovantIMVT $6.6Bloss–––
Scholar RockSRRK $5.9Blossover 999––
Twist BioscienceTWST $7.0Bloss15.3+22%-28.3%
CG OncologyCGON $7.1Blossover 999+184%–

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$178.6M

bought $181.3M, sold $2.7M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+8.0%

215 13F filers vs 199

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

92%

60.2M shares held by 13F filers (30 Sep 2026) of 65.4M outstanding (9 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

12%

8.1M shares sold short (30 Oct 2026) of 65.4M outstanding (9 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

9.3

8.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-4.5%

8.5M shares sold short in the report before, 8.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

59%

59% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 59%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

9

9 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

9 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $97.17 on 20 Nov 2026, +396% over 12 months (12-month range $19.59 to $111.19)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $236.4M in the last 12 months (the 12 months before: -$3K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 4 published in the last 12 months, +33% on the 12 months before.
Capital spending per quarter. Capital spending $2.0M in the latest quarter, +3200% on a year earlier.
Institutional holders (13F filers). 215 13F filers reported holding it in the latest 13F quarter, +89% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
28 Apr 2026Sharp changeShort interest spike: short interest spike, 10.3M vs usual 3.8M (2026-04-15); 3.0x the same period a year earlier
14 Apr 2026Sharp changeShort interest spike: short interest spike, 9.9M vs usual 3.7M (2026-03-31); 3.1x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 7.3M vs usual 3.1M (2026-01-30); 3.6x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 7.1M vs usual 3.0M (2026-01-15); 4.2x the same period a year earlier
2 Apr 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 27.5M vs usual 8.2M (2023-12-31); 9.0x the same period a year earlier
17 Aug 20238-K and other filingsDirector or officer change
17 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 May 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 17.5M vs usual 1.8M (2022-03-31); 14.1x the same period a year earlier
8 Mar 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 8.4M vs usual 1.4M (2021-12-31); 4.3x the same period a year earlier
Insider net buying (open market)
Month from 1 Nov 2021: -$689K published
Month from 1 Dec 2021: -$609K published
Month from 1 Jan 2022: $28.4M published
Month from 1 Feb 2022: $39.9M published
Month from 1 Mar 2022: -$12.3M published
Month from 1 May 2022: $5.1M published
Month from 1 Jun 2022: $4.4M published
Month from 1 Jun 2023: -$71K published
Month from 1 Jun 2024: -$12K published
Month from 1 Jun 2025: -$3K published
Month from 1 Dec 2025: $60.0M published
Month from 1 Apr 2026: -$1.2M published
Month from 1 Jun 2026: -$1.0M published
Month from 1 Oct 2026: $154.3M published
Month from 1 Nov 2026: $24.3M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 1 published
Quarter from 1 Apr 2022: 1 published
Quarter from 1 Jul 2022: 1 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Jul 2024: 6 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Oct 2025: 2 published
Quarter from 1 Jul 2026: 2 published
Quarter from 1 Oct 2026: 2 published
Capital spending per quarter
Quarter ended 31 Dec 2021: $8.4M, +331% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $17.5M, +1311% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $8.2M, +225% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $8.3M, +71% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $3.1M, -64% on a year earlier; public on 29 Mar 2023
Quarter ended 31 Mar 2023: $12.2M, -30% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $1.5M, -82% on a year earlier; public on 15 Aug 2023
Quarter ended 31 Dec 2023: $27.5M, +797% on a year earlier; public on 29 Mar 2024
Quarter ended 31 Mar 2024: $22K, -100% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $49K, -97% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $180K; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $124K, -100% on a year earlier; public on 28 Mar 2025
Quarter ended 31 Mar 2025: $270K, +1127% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $133K, +171% on a year earlier; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $60K, -67% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $43K, -65% on a year earlier; public on 1 Apr 2026
Quarter ended 31 Mar 2026: $942K, +249% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $352K, +165% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $2.0M, +3200% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 141; public on 14 Feb 2022
31 Mar 2022 report: 129; public on 16 May 2022
30 Jun 2022 report: 121; public on 15 Aug 2022
30 Sep 2022 report: 125; public on 14 Nov 2022
31 Dec 2022 report: 121; public on 14 Feb 2023
31 Mar 2023 report: 116; public on 15 May 2023
30 Jun 2023 report: 120; public on 14 Aug 2023
30 Sep 2023 report: 92; public on 14 Nov 2023
31 Dec 2023 report: 90; public on 14 Feb 2024
31 Mar 2024 report: 108; public on 15 May 2024
30 Jun 2024 report: 98; public on 14 Aug 2024
30 Sep 2024 report: 92; public on 14 Nov 2024
31 Dec 2024 report: 104; public on 14 Feb 2025
31 Mar 2025 report: 103; public on 15 May 2025
30 Jun 2025 report: 96; public on 14 Aug 2025
30 Sep 2025 report: 114; public on 14 Nov 2025
31 Dec 2025 report: 154; public on 17 Feb 2026
31 Mar 2026 report: 185; public on 15 May 2026
30 Jun 2026 report: 199; public on 14 Aug 2026
30 Sep 2026 report: 215; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $24.3M (6 Nov 2026), higher than 91% of its own history.
  • Insider net buying (open market): Insiders bought a net $236.4M in the last 12 months (the 12 months before: -$3K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 4 published in the last 12 months, +33% on the 12 months before.
  • Capital spending per quarter: Capital spending $2.0M in the latest quarter, +3200% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 76 insider trades

Last 90 days: 1 sale, $2.7M; 4 purchases, $181.3M. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
6 Nov 2026Baker Bros. Advisors LP and 5 othersDirector, 10% ownerBuy247,090$98.51$24.3MForm 4
23 Oct 2026John A. BorgesonChief Financial OfficerSellplanned in advance (10b5-1); after exercising options30,000$90.01$2.7MForm 4
30 Sep 2026667, L.P. and 5 othersDirector, 10% ownerBuy715,592$88.60$63.4MForm 4
30 Sep 2026Baker Bros. Advisors (GP) LLC and 5 othersDirector, 10% ownerBuy807,840$72.57$58.6MForm 4
30 Sep 2026Julian Baker and 5 othersDirector, 10% ownerBuy418,323$83.58$35.0MForm 4
5 Jun 2026John A. BorgesonChief Financial OfficerSellplanned in advance (10b5-1); after exercising options30,000$34.10$1.0MForm 4
2 Apr 2026John A. BorgesonChief Financial OfficerSellplanned in advance (10b5-1); after exercising options30,000$39.92$1.2MForm 4
19 Dec 2025Baker Brothers Life Sciences LP and 5 othersDirector, 10% ownerBuy2,608,696$23.00$60.0MForm 4

215 institutions reported shares at the end of Q3 2026, 92% of the shares outstanding; 46 opened a position, 32 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Baker Bros. Advisors LP21.9M33.4%$2.1B+1.9M+9.7%
BlackRock, Inc.3.8M5.83%$361.6M-321K-7.8%
T. Rowe Price Associates Inc2.9M4.49%-315K-9.7%
State Street Corp2.2M3.41%$211.3M-190K-7.9%
Goldman Sachs Group Inc2.0M3.04%$188.7M-326K-14%
T. Rowe Price Investment Management, Inc.2.0M3.01%+494K+33%
Janus Henderson Group Ltd.1.9M2.87%$178.0M
Vanguard Capital Management LLC1.8M2.72%$168.5M-27K-1.5%
RTW Investments, LP1.5M2.28%$141.1MNo change
Boxer Capital Management, LLC1.5M2.26%$140.1MNo change

Company events

All 14 company events

Nothing in 12 months; the latest was filed 17 Aug 2023. Results releases and routine reports are left out.

FiledWhat happenedSource
17 Aug 2023Director or officer change8-K
15 Oct 2021Director or officer changeSame filing: shareholder vote results8-K
22 Jul 2021Signed a major agreement8-K
25 Jun 2020Signed a major agreement8-K
3 Apr 2020Director or officer change8-K
19 Dec 2019Director or officer change8-K
2 Dec 2019Signed a major agreement8-K
10 Oct 2019Delisting notice or listing transfer8-K

The 5 newest of 150 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 6 Nov 2026Insiders record

    BAKER BROS. ADVISORS LP (director) and 5 other(s) bought 247,090 shares of KOD ($24.3M)

  2. 1 Oct 2026Insiders record

    667, L.P. (director) and 5 other(s) bought 715,592 shares of KOD ($63.4M) (dated 30 Sep 2026)

  3. 1 Oct 2026Insiders record

    Baker Bros. Advisors (GP) LLC (director) and 5 other(s) bought 807,840 shares of KOD ($58.6M) (dated 30 Sep 2026)

  4. 1 Oct 2026Insiders record

    BAKER JULIAN (director) and 5 other(s) bought 418,323 shares of KOD ($35.0M) (dated 30 Sep 2026)

  5. 25 Apr 2026Short interest and volume change

    had 10.3M shares sold short in the 15 Apr 2026 report, 3.0× the same report last year.

    Same report last year: 3.5M; its normal report is 3.8M.

    See the evidence
    This period
    10.3M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +3.8
    Same report last year
    3.5M
    History used
    2,739 days
    2025-04-15: 3.5M2025-04-30: 3.6M2025-05-15: 3.4M2025-05-30: 2.3M2025-06-13: 2.0M2025-06-30: 2.2M2025-07-15: 2.5M2025-07-31: 2.5M2025-08-15: 2.8M2025-08-29: 2.9M2025-09-15: 3.1M2025-09-30: 3.8M2025-10-15: 3.8M2025-10-31: 4.3M2025-11-14: 4.5M2025-11-28: 4.8M2025-12-15: 4.7M2025-12-31: 6.3M2026-01-15: 7.1M2026-01-30: 7.3M2026-02-13: 6.9M2026-02-27: 7.0M2026-03-13: 7.0M2026-03-31: 9.9M2026-04-15: 10.3M
    the 15 Apr 2026 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 11 Apr 2026Short interest and volume change

    had 9.9M shares sold short in the 31 Mar 2026 report, 3.1× the same report last year.

    Same report last year: 3.2M; its normal report is 3.7M.

    See the evidence
    This period
    9.9M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +4.0
    Same report last year
    3.2M
    History used
    2,724 days
    2025-03-31: 3.2M2025-04-15: 3.5M2025-04-30: 3.6M2025-05-15: 3.4M2025-05-30: 2.3M2025-06-13: 2.0M2025-06-30: 2.2M2025-07-15: 2.5M2025-07-31: 2.5M2025-08-15: 2.8M2025-08-29: 2.9M2025-09-15: 3.1M2025-09-30: 3.8M2025-10-15: 3.8M2025-10-31: 4.3M2025-11-14: 4.5M2025-11-28: 4.8M2025-12-15: 4.7M2025-12-31: 6.3M2026-01-15: 7.1M2026-01-30: 7.3M2026-02-13: 6.9M2026-02-27: 7.0M2026-03-13: 7.0M2026-03-31: 9.9M
    the 31 Mar 2026 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 11 Feb 2026Short interest and volume change

    had 7.3M shares sold short in the 30 Jan 2026 report, 3.6× the same report last year.

    Same report last year: 2.0M; its normal report is 3.1M.

    See the evidence
    This period
    7.3M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    745K
    How far from its usual level
    +3.8
    Same report last year
    2.0M
    History used
    2,664 days
    2025-01-31: 2.0M2025-02-14: 2.0M2025-02-28: 2.3M2025-03-14: 2.7M2025-03-31: 3.2M2025-04-15: 3.5M2025-04-30: 3.6M2025-05-15: 3.4M2025-05-30: 2.3M2025-06-13: 2.0M2025-06-30: 2.2M2025-07-15: 2.5M2025-07-31: 2.5M2025-08-15: 2.8M2025-08-29: 2.9M2025-09-15: 3.1M2025-09-30: 3.8M2025-10-15: 3.8M2025-10-31: 4.3M2025-11-14: 4.5M2025-11-28: 4.8M2025-12-15: 4.7M2025-12-31: 6.3M2026-01-15: 7.1M2026-01-30: 7.3M
    the 30 Jan 2026 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 28 Jan 2026Short interest and volume change

    had 7.1M shares sold short in the 15 Jan 2026 report, 4.2× the same report last year.

    Same report last year: 1.7M; its normal report is 3.0M.

    See the evidence
    This period
    7.1M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    3.0M
    Typical spread (median absolute deviation)
    738K
    How far from its usual level
    +3.8
    Same report last year
    1.7M
    History used
    2,649 days
    2025-01-15: 1.7M2025-01-31: 2.0M2025-02-14: 2.0M2025-02-28: 2.3M2025-03-14: 2.7M2025-03-31: 3.2M2025-04-15: 3.5M2025-04-30: 3.6M2025-05-15: 3.4M2025-05-30: 2.3M2025-06-13: 2.0M2025-06-30: 2.2M2025-07-15: 2.5M2025-07-31: 2.5M2025-08-15: 2.8M2025-08-29: 2.9M2025-09-15: 3.1M2025-09-30: 3.8M2025-10-15: 3.8M2025-10-31: 4.3M2025-11-14: 4.5M2025-11-28: 4.8M2025-12-15: 4.7M2025-12-31: 6.3M2026-01-15: 7.1M
    the 15 Jan 2026 report24 earlier reportsnormal: 3.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 20 Dec 2025Insiders record

    Baker Brothers Life Sciences LP (director) and 5 other(s) bought 2,608,696 shares of KOD ($60.0M) (dated 19 Dec 2025)

  10. 2 Apr 2024Financials change

    spent $27.5M on capital projects in the quarter ended 31 Dec 2023, 9.0× the same quarter last year.

    Same quarter last year: $3.1M; its normal quarter is $8.2M.

    See the evidence
    This period
    $27.5M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $8.2M
    Typical spread (median absolute deviation)
    $3.7M
    How far from its usual level
    +3.5
    Same quarter last year
    $3.1M
    History used
    2,191 days
    2021-09-30: $4.8M2021-12-31: $8.4M2022-03-31: $17.5M2022-06-30: $8.2M2022-09-30: $8.3M2022-12-31: $3.1M2023-03-31: $12.2M2023-06-30: $1.5M2023-12-31: $27.5M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $8.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  11. 17 Aug 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 17 Aug 2023Filings record

    Director or officer change

  13. 7 Jun 2022Insiders record

    Baker Bros. Advisors (GP) LLC (director) and 5 other(s) bought 572,349 shares of KOD ($4.4M) (dated 6 Jun 2022)

  14. 28 May 2022Insiders record

    BAKER FELIX (director) and 5 other(s) bought 350,406 shares of KOD ($2.4M) (dated 27 May 2022)

  15. 19 May 2022Insiders record

    Baker Brothers Life Sciences LP (director) and 5 other(s) bought 456,690 shares of KOD ($2.7M) (dated 18 May 2022)

  16. 17 May 2022Financials change

    spent $17.5M on capital projects in the quarter ended 31 Mar 2022, 14× the same quarter last year.

    Same quarter last year: $1.2M; its normal quarter is $1.8M.

    See the evidence
    This period
    $17.5M (the quarter ended 31 Mar 2022)
    Normal quarter (median of 8 earlier)
    $1.8M
    Typical spread (median absolute deviation)
    $1.2M
    How far from its usual level
    +9.0
    Same quarter last year
    $1.2M
    History used
    1,551 days
    2019-12-31: $153K2020-03-31: $180K2020-09-30: $1.6M2020-12-31: $2.0M2021-03-31: $1.2M2021-06-30: $2.5M2021-09-30: $4.8M2021-12-31: $8.4M2022-03-31: $17.5M
    the quarter ended 31 Mar 20228 earlier quartersnormal: $1.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  17. 8 Mar 2022Financials change

    spent $8.4M on capital projects in the quarter ended 31 Dec 2021, 4.3× the same quarter last year.

    Same quarter last year: $2.0M; its normal quarter is $1.4M.

    See the evidence
    This period
    $8.4M (the quarter ended 31 Dec 2021)
    Normal quarter (median of 8 earlier)
    $1.4M
    Typical spread (median absolute deviation)
    $1.2M
    How far from its usual level
    +4.0
    Same quarter last year
    $2.0M
    History used
    1,461 days
    2019-09-30: $158K2019-12-31: $153K2020-03-31: $180K2020-09-30: $1.6M2020-12-31: $2.0M2021-03-31: $1.2M2021-06-30: $2.5M2021-09-30: $4.8M2021-12-31: $8.4M
    the quarter ended 31 Dec 20218 earlier quartersnormal: $1.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  18. 18 Feb 2022Insiders record

    Baker Brothers Life Sciences LP (director) and 5 other(s) bought 400,965 shares of KOD ($21.8M) (dated 17 Feb 2022)

  19. 1 Feb 2022Insiders record

    BAKER BROS. ADVISORS LP (director) and 5 other(s) bought 347,665 shares of KOD ($18.1M) (dated 31 Jan 2022)

  20. 26 Jan 2022Insiders record

    BAKER FELIX (director) and 5 other(s) bought 501,111 shares of KOD ($28.8M) (dated 25 Jan 2022)

  21. 15 Oct 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 15 Oct 2021Filings record

    Director or officer change

  23. 2 Oct 2021Insiders record

    BAKER BROS. ADVISORS LP (director) and 5 other(s) bought 86,932 shares of KOD ($8.3M) (dated 1 Oct 2021)

  24. 18 Sep 2021Insiders record

    Baker Brothers Life Sciences LP (director) and 5 other(s) bought 31,838 shares of KOD ($3.0M) (dated 17 Sep 2021)

  25. 10 Sep 2021Insiders record

    Baker Bros. Advisors (GP) LLC (director) and 5 other(s) bought 57,501 shares of KOD ($5.4M) (dated 9 Sep 2021)

  26. 20 Aug 2021Insiders record

    667, L.P. (director) and 5 other(s) bought 114,396 shares of KOD ($10.0M) (dated 19 Aug 2021)

  27. 14 Aug 2021Insiders record

    Baker Bros. Advisors (GP) LLC (director) and 5 other(s) bought 102,773 shares of KOD ($9.0M) (dated 13 Aug 2021)

  28. 1 Jul 2021Insiders record

    Baker Brothers Life Sciences LP (director) and 5 other(s) bought 257,929 shares of KOD ($23.7M) (dated 30 Jun 2021)

  29. 25 Nov 2020Insiders record

    Baker Brothers Life Sciences LP (director) and 5 other(s) bought 1,527,777 shares of KOD ($165.0M) (dated 24 Nov 2020)

  30. 26 Sep 2020Insiders record

    BAKER FELIX (director) and 5 other(s) bought 48,125 shares of KOD ($2.7M) (dated 25 Sep 2020)

  31. 25 Sep 2020Insiders record

    Baker Brothers Life Sciences LP (director) and 5 other(s) bought 203,047 shares of KOD ($10.5M) (dated 24 Sep 2020)

  32. 9 Sep 2020Insiders record

    BAKER JULIAN (director) and 5 other(s) bought 322,979 shares of KOD ($15.3M) (dated 8 Sep 2020)

  33. 22 Aug 2020Insiders record

    BAKER BROS. ADVISORS LP (director) and 5 other(s) bought 203,486 shares of KOD ($9.8M) (dated 21 Aug 2020)

  34. 3 Apr 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 3 Apr 2020Filings record

    Director or officer change

  36. 25 Mar 2020Short interest and volume change

    had 3.7M shares sold short in the 13 Mar 2020 report, 14× the same report last year.

    Same report last year: 256K; its normal report is 566K.

    See the evidence
    This period
    3.7M (the 13 Mar 2020 report)
    Normal report (median of 24 earlier)
    566K
    Typical spread (median absolute deviation)
    400K
    How far from its usual level
    +5.3
    Same report last year
    256K
    History used
    515 days
    2019-03-15: 256K2019-03-29: 279K2019-04-15: 208K2019-04-30: 196K2019-05-15: 172K2019-05-31: 208K2019-06-14: 159K2019-06-28: 210K2019-07-15: 531K2019-07-31: 532K2019-08-15: 547K2019-08-30: 529K2019-09-13: 586K2019-09-30: 1.0M2019-10-15: 1.2M2019-10-31: 2.1M2019-11-15: 2.7M2019-11-29: 2.4M2019-12-13: 2.2M2019-12-31: 2.9M2020-01-15: 2.6M2020-01-31: 2.8M2020-02-14: 3.3M2020-02-28: 3.8M2020-03-13: 3.7M
    the 13 Mar 2020 report24 earlier reportsnormal: 566K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 25 Mar 2020Insiders record

    Levy Richard S (director) bought 1,000 shares of KOD ($44,330) (dated 24 Mar 2020)

  38. 19 Mar 2020Insiders record

    BAKER FELIX (director) and 5 other(s) bought 150,000 shares of KOD ($5.9M) (dated 18 Mar 2020)

  39. 11 Mar 2020Short interest and volume change

    had 3.8M shares sold short in the 28 Feb 2020 report, 23× the same report last year.

    Same report last year: 162K; its normal report is 540K.

    See the evidence
    This period
    3.8M (the 28 Feb 2020 report)
    Normal report (median of 24 earlier)
    540K
    Typical spread (median absolute deviation)
    373K
    How far from its usual level
    +5.9
    Same report last year
    162K
    History used
    501 days
    2019-02-28: 162K2019-03-15: 256K2019-03-29: 279K2019-04-15: 208K2019-04-30: 196K2019-05-15: 172K2019-05-31: 208K2019-06-14: 159K2019-06-28: 210K2019-07-15: 531K2019-07-31: 532K2019-08-15: 547K2019-08-30: 529K2019-09-13: 586K2019-09-30: 1.0M2019-10-15: 1.2M2019-10-31: 2.1M2019-11-15: 2.7M2019-11-29: 2.4M2019-12-13: 2.2M2019-12-31: 2.9M2020-01-15: 2.6M2020-01-31: 2.8M2020-02-14: 3.3M2020-02-28: 3.8M
    the 28 Feb 2020 report24 earlier reportsnormal: 540K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 27 Feb 2020Short interest and volume change

    had 3.3M shares sold short in the 14 Feb 2020 report, 21× the same report last year.

    Same report last year: 159K; its normal report is 531K.

    See the evidence
    This period
    3.3M (the 14 Feb 2020 report)
    Normal report (median of 24 earlier)
    531K
    Typical spread (median absolute deviation)
    364K
    How far from its usual level
    +5.0
    Same report last year
    159K
    History used
    487 days
    2019-02-15: 159K2019-02-28: 162K2019-03-15: 256K2019-03-29: 279K2019-04-15: 208K2019-04-30: 196K2019-05-15: 172K2019-05-31: 208K2019-06-14: 159K2019-06-28: 210K2019-07-15: 531K2019-07-31: 532K2019-08-15: 547K2019-08-30: 529K2019-09-13: 586K2019-09-30: 1.0M2019-10-15: 1.2M2019-10-31: 2.1M2019-11-15: 2.7M2019-11-29: 2.4M2019-12-13: 2.2M2019-12-31: 2.9M2020-01-15: 2.6M2020-01-31: 2.8M2020-02-14: 3.3M
    the 14 Feb 2020 report24 earlier reportsnormal: 531K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 62 entries; narrow the window or the kind of data to see older ones.

Not listed: 136 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001468748
Ticker
KOD
Domain
kodiak.com
Employer name
Kodiak Sciences, Inc. (1 unverified)
Hq location
CA|PALO ALTO|94304 (1 unverified)
Name
Kodiak Sciences Financing Corporation, Kodiak Sciences Inc, Kodiak Sciences Valais GmbH, Oligasis, LLC
Wikidata
Q106301447
  • DOL H-1B labor condition applications and PERM certifications102 data points1 Feb 2021 to 24 Aug 2026
  • SEC Form 13F institutional holdings306 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)99 records23 Mar 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)491 data points31 Dec 2015 to 9 Nov 2026
  • SEC Form 4 insider transactions76 records, 272 data points9 Oct 2018 to 6 Nov 2026
  • FINRA short interest (twice monthly)578 data points15 Oct 2018 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4088 data points4 Oct 2018 to 20 Nov 2026